Tag:
Cancer Drugs
Latest Headlines
Latest Headlines
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Cancer drug developers angling for center stage at ASCO
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
Support seen for U.S. plan to speed nods for 'breakthrough' drugs
This year the agency and U.S. lawmakers appear to be supportive of a plan that would help pharma groups race to the market with breakthrough drugs.
FDA withdraws hold on GTx's prostate cancer drug
The FDA lifted a clinical hold on the experimental cancer drug Capesaris after reviewing the company's response and plans for a Phase II study involving patients with castration-resistant prostate cancer.
Talon sinks after FDA prolongs cancer drug review
Investors have kicked Talon's shares into penny-stock territory after the company revealed that U.S. regulators want more time to review its experimental blood-cancer drug.
Aveo Pharma flunks Phase II lung cancer study
Aveo's share price slid a modest 30 cents, or 2.53%, to $11.77, as of 10:30 a.m. ET Wednesday.
Readers' picks, responses to Fierce's 'Top 10' cancer drugs report
I've tried to capture some of the most interesting responses we've gotten over the past few days since we published our 2012 report .
Top 10 late-stage cancer drugs in 2012
Thousands of experimental meds are winding their way through various stages of clinical trials today, and the largest category among the contenders is cancer drugs.
Nanomedicine standout spotlights first human cancer data
Bind Biosciences has scored some initial blows against cancers in humans, providing data that back up some of the promise of its nanomedicine Bind-014 in preclinical tests.
Merrimack Pharma stumbles out of the IPO gate
Merrimack's shares fell 13.7% from the opening price of $7 per share, giving the developer of cancer drugs a lackluster public debut.
